Quick Answer
Lyra Therapeutics, Inc. reported Shares Outstanding of 1.77 million shares for fiscal year 2025.
Lyra Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 1.77M | +35.5% |
| 2024 | 1.31M | -97.7% |
| 2023 | 57.21M | +79.8% |
| 2022 | 31.83M | +144.7% |
| 2021 | 13.01M | +0.6% |
| 2020 | 12.93M | +5501.8% |
| 2019 | 230,860 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 1.64M | -97.5% | +1.2% |
| June 30, 2025 | 1.63M | -97.5% | -97.5% |
| March 31, 2025 | 65.88M | +8.1% | +4927.9% |
| December 31, 2024 | 1.31M | -97.7% | -98.0% |
| September 30, 2024 | 65.46M | +32.1% | +0.0% |
| June 30, 2024 | 65.46M | +32.1% | +7.4% |
| March 31, 2024 | 60.96M | +91.5% | +6.6% |
| December 31, 2023 | 57.21M | +79.8% | +15.5% |
- Lyra Therapeutics, Inc. showed an increase of +35.5% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s shares outstanding has grown by 668.8% (from 230.9 thousand shares to 1.77 million shares).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: